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 2015-2016 Northern Hemisphere and U.S. Influenza Vaccine Composition  
 Influenza-Associated Pediatric Deaths Updated!  
 
Summary Key Messages  
 This week’s FluView (http://www.cdc.gov/flu/weekly/) report indicates that influenza 
activity is low in the United States. 
 CDC posted an end-of-season spotlight on April 27, 2015 available at: 
http://www.cdc.gov/flu/news/2014-2015-flu-season-wrapup.htm.  
 Antiviral drugs are a second line of defense against influenza and can be used to treat 
flu illness.  
 CDC recommends that all hospitalized and high-risk patients (either hospitalized or 
outpatient) with suspected influenza should be treated as soon as possible with 
influenza antiviral medications without waiting for confirmatory influenza testing. For 
further guidance on the appropriate use of antiviral agents and dosing information, see 
CDC’s Summary of Influenza Antiviral Treatment Recommendations for Clinician 
(http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm).  
 While antiviral drugs work best when given early, therapeutic benefit has been 
observed even when treatment is initiated later. 
 
FluView Activity Update 
 According to this week’s FluView report, flu activity continues to decline and flu-like 
illness is below national baseline levels for the third week. However, three states 
(Connecticut, Massachusetts, and New York) continue to report widespread flu activity.    
 Influenza B viruses now account for 89% of all influenza viruses reported. Influenza 
viruses circulate year-round, though at low levels in the summer in the United States. 
 Below is a summary of the key flu indicators for the week ending April 25, 2015: 
o For the week ending April 25, the proportion of people seeing their health care 
provider (http://www.cdc.gov/flu/weekly/index.htm#OISmap) for influenza-like 
illness (ILI) remained at 1.4%, and is below the national baseline of 2.0% for 
the third week.  However, two of 10 regions (Regions 1 and 8) reported ILI at or 
above region-specific baseline levels. ILI was above or at baseline for 20 weeks 
this season, making this the longest season in more than a decade. For the past 
13 seasons, ILI has remained at or above the national baseline for between one 
and 19 weeks each season. 
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o New York City and 49 states experienced minimal ILI activity 
(http://www.cdc.gov/flu/weekly/index.htm#ilimap). The District of Columbia 
and one state (Colorado) did not have sufficient data to calculate an activity 
level. Puerto Rico experienced low ILI activity. ILI activity data indicate the 
amount of flu-like illness that is occurring in each state. 
o Widespread influenza activity was reported by three states (Connecticut, 
Massachusetts, and New York); the same states reported widespread flu activity 
during the previous week. Guam and nine states reported regional geographic 
influenza (http://www.cdc.gov/flu/weekly/#S5) activity. Local flu activity was 
reported by Puerto Rico and 14 states. Sporadic flu activity was reported by the 
District of Columbia, the U.S. Virgin Islands, and 21 states. Three states 
reported no influenza activity; an increase from two states during the previous 
week. Geographic spread data show how many areas within a state or territory 
are seeing flu activity. 
o A total of 17,584 laboratory-confirmed influenza-associated hospitalizations 
(http://www.cdc.gov/flu/weekly/#S6) have been reported through the Influenza 
Hospitalization Surveillance Network (FluSurv-NET) since October 1, 2014. This 
translates to a cumulative overall rate of 64.3 hospitalizations per 100,000 
population. This is higher than the cumulative overall hospitalization rate during 
2012-2013, which was 43.9 per 100,000 people. 
 The hospitalization rate in people 65 years and older is 316.8 per 
100,000, which is the highest hospitalization rate recorded since data 
collection on laboratory-confirmed influenza-associated hospitalization in 
adults began during the 2005-2006 season. This is the highest rate of any 
age group. Last week, the hospitalization rate in people 65 years and 
older was 313.8 per 100,000. Previously, the highest recorded 
hospitalization rate was 183.2 per 100,000, which was the cumulative 
hospitalization rate for people 65 years and older for the 2012-2013 
season. (The 2012-2013 season was the last H3N2-predominant season.) 
 The hospitalization rate for children 0-4 years is 56.4 per 100,000 
population. During the 2012-2013 season, the overall hospitalization rate 
for that age group was 67.0 per 100,000 cumulatively that season. 
 Hospitalization data are collected from 13 states and represent 
approximately 9% of the total U.S. population. The number of 
hospitalizations reported does not reflect the actual total number of 
influenza-associated hospitalizations in the United States. 
o The proportion of deaths (http://www.cdc.gov/flu/weekly/index.htm#S2) 
attributed to pneumonia and influenza (P&I) based on the 122 Cities Mortality 
Reporting System was 6.7%, and remains below the epidemic threshold of 
6.9%. The percentage of P&I attributed deaths was at or above the epidemic 
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threshold for 12 consecutive weeks this season. The highest P&I percentage this 
season was 9.3% and occurred during week 2. During 2012-2013, P&I peaked 
at 9.9%. This is comparable to recorded percentages for past severe seasons, 
including the 2003-2004 season when P&I reached 10.4%. 
o Five influenza-associated pediatric deaths (http://www.cdc.gov/flu/weekly 
/index.htm#S3) were reported to CDC during the week ending April 25.  
 Two deaths were associated with an influenza A (H3) virus and occurred 
during weeks 3 and 8 (the weeks ending January 24 and February 28, 
2015, respectively).  Three deaths were associated with an influenza B 
virus and occurred during weeks 10, 12, and 15 (the weeks ending March 
14, March 28, and April 18, 2015, respectively). 
 A total of 133 influenza-associated pediatric deaths have been reported 
for the 2014-2015 season at this time.  
o Nationally, the percentage of respiratory specimens (http://www.cdc.gov/flu 
/weekly/index.htm#S1) testing positive for influenza viruses in the United 
States during the week ending April 25 slightly decreased from 7.6% to 6.5%. 
For the most recent three weeks, the regional percentage of respiratory 
specimens testing positive for influenza viruses ranged from 4.2% to 14.6%. 
o Influenza A (H3N2) viruses (http://www.cdc.gov/flu/weekly/index.htm 
#whomap) have predominated overall during the 2014-2015 flu season, 
accounting for more than 99% of all subtyped influenza A viruses. However 
influenza B viruses have accounted for the largest proportion of circulating 
viruses since early March. During week 16, 89% of all influenza positive 
specimens reported were influenza B viruses, and influenza B viruses 
predominated in all 10 regions. It is not uncommon for there to be a second 
wave of flu activity toward the end of the flu season with another seasonal 
influenza virus. Influenza A (H1N1) pdm09 viruses have been detected rarely 
this season. 
o CDC has antigenically or genetically characterized (http://www.cdc.gov/flu 
/professionals/laboratory/antigenic.htm) 1,865 influenza viruses, including 49 
influenza A (H1N1)pdm09, 1,220 influenza A (H3N2) viruses and 596 influenza 
B viruses, collected in the United States since October 1, 2014.  
 All 49 influenza A (H1N1)pdm09 viruses tested were characterized as 
A/California/7/2009-like. This is the influenza A (H1N1) component of the 
2014-2015 Northern Hemisphere quadrivalent and trivalent influenza 
vaccine. 
 243 (19.9%) of the 1,220 influenza A (H3N2) viruses tested have been 
characterized as A/Texas/50/2012-like. This is the influenza A (H3N2) 
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component of the 2014-2015 Northern Hemisphere quadrivalent and 
trivalent influenza vaccine. 
 The remaining 977 (80.1%) influenza A (H3N2) viruses tested were 
different from A/Texas/50/2012. The majority of these 977 influenza A 
(H3N2) viruses were antigenically similar to 
A/Switzerland/9715293/2013, the influenza A (H3N2) component of the 
2015 Southern Hemisphere influenza vaccine and 2015-2016 Northern 
Hemisphere influenza vaccine. 
 396 (97.3%) of the 407 B/Yamagata-lineage viruses were characterized 
as B/Massachusetts/2/2012-like, which is included as an influenza B 
component of the 2014-2015 Northern Hemisphere trivalent and 
quadrivalent influenza vaccines. Eleven (2.7%) of the B/Yamagata-lineage 
viruses tested showed reduced titers to B/Massachusetts/2/2012.  
 184 (97.4%) of the 189 other influenza B viruses belonged to the 
B/Victoria lineage of viruses, and were characterized as 
B/Brisbane/60/2008-like. This is the recommended influenza B 
component of the 2014-2015 Northern Hemisphere quadrivalent influenza 
vaccine. Five (2.6%) of the B/Victoria-lineage viruses tested showed 
reduced titers to B/Brisbane/60/2008. 
o Since October 1, 2014, CDC has tested 47 influenza A (H1N1)pdm09, 3,032 
influenza A (H3N2), and 621 influenza B viruses for resistance to neuraminidase 
inhibitors (oseltamivir, zanamivir, and peramivir). While the vast majority of the 
viruses that have been tested are sensitive to oseltamivir, zanamivir, and 
peramivir, so far this season, one influenza A (H1N1)pdm09 virus showed 
resistance to oseltamivir and peramivir. (Because H1N1 viruses have been so 
rare this season, one virus accounts for 2.1% of the H1N1 viruses analyzed for 
antiviral resistance this season.) 
 Previously, the neuraminidase inhibitors oseltamivir and zanamivir were 
the only recommended influenza antiviral drugs (http://www.cdc.gov/flu 
/antivirals/index.htm). On December 19, 2014, the U.S. Food and Drug 
Administration approved Rapivab (peramivir) (http://www.fda.gov 
/NewsEvents/Newsroom/PressAnnouncements/ucm427755.htm) to treat 
influenza infection in adults. 
 As in recent past seasons, high levels of resistance to the adamantanes 
(amantadine and rimantadine) continue to persist among influenza A 
(H1N1)pdm09 and influenza A (H3N2) viruses. Adamantanes are not 
effective against influenza B viruses.  
o FluView (http://www.cdc.gov/flu/weekly) is available – and past issues are 
archived (http://www.cdc.gov/flu/weekly/pastreports.htm) – on CDC’s website. 
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Note: Delays in reporting may mean that data changes over time. The most up to date 
data for all weeks during the 2014-2015 season can be found on the current FluView 
(http://www.cdc.gov/flu/weekly). 
 
2015-2016 Northern Hemisphere and U.S. Influenza Vaccine Composition  
 Influenza viruses are always changing.  
 The composition of the Northern Hemisphere seasonal influenza vaccine is reviewed 
annually and updated as needed to increase the likelihood that circulating influenza 
viruses and vaccine viruses will be similar during the upcoming season.  
 Experts review global influenza laboratory and surveillance data and data on the 
candidate vaccine viruses that are available for vaccine production.  
 The similarity between vaccine viruses and circulating influenza viruses is one 
important factor that contributes to how well the vaccine works. 
 The World Health Organization (WHO) meets to make the vaccine composition 
recommendation for the entire Northern Hemisphere. The U.S. Food and Drug 
Administration’s Vaccines and Related Biological Products Advisory Committee 
(VRBPAC) convenes after the WHO meeting to make the recommendation for the 
vaccine composition for the United States. 
 On February 25-26, 2015, international experts from CDC and other Collaborating 
Centers and Essential Regulatory Laboratories (http://www.who.int/influenza/gisrs 
_laboratory/collaborating_centres/list/en/), such as FDA, gathered at the World Health 
Organization (WHO) Consultation and Information meeting (http://www.who.int 
/influenza/vaccines/virus/recommendations/consultation201502/en/) to review the 
data and recommend the vaccine composition for the upcoming Northern Hemisphere 
2015-2016 influenza vaccine. 
 WHO selected the following vaccine viruses: 
o an A/California/7/2009 (H1N1)pdm09-like virus, which is the same strain for the 
2014-15 influenza vaccine 
o an A/Switzerland/9715293/2013 (H3N2)-like virus, which is a different strain 
from the 2014-15 influenza vaccine (but the same strain selected in September 
2014 for the 2015 Southern Hemisphere vaccine) 
o a B/Phuket/3073/2013-like (B/Yamagata lineage) virus, which is a different 
strain from the 2014-15 influenza vaccine  (but the same strain selected for the 
2015 Southern Hemisphere vaccine) 
o WHO also recommended that quadrivalent vaccines with two influenza B viruses 
contain the above three viruses and a B/Brisbane/60/2008-like (B/Victoria 
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lineage) virus, which is the same strain recommended as a second influenza B 
strain for the 2014-2015 quadrivalent vaccines. 
 On March 4, 2015 (http://www.fda.gov/AdvisoryCommittees 
/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiol
ogicalProductsAdvisoryCommittee/ucm436058.htm), FDA’s VRBPAC met and 
considered the recommendations made by the WHO regarding the composition of 
influenza virus vaccines for the upcoming influenza season (2015-2016) in the 
Northern Hemisphere. The committee reviewed the data gathered from the 2014-2015 
strains of influenza viruses that are infecting humans, including data on how the 
strains are changing, and also reviewed disease trends in order to forecast which 
viruses are likely to circulate, and to formulate recommendations for the composition 
of the 2015-2016 influenza vaccine.   
 FDA’s VRBPAC reached consensus and concluded that the WHO-recommended 
influenza viruses should be used as the composition for the U.S. 2015-2016 influenza 
vaccines.  
 The recommended (http://www.who.int/influenza/vaccines/virus 
/recommendations/consultation201502/en/) vaccine viruses for the 2015-2016 
Northern Hemisphere and the United States influenza season are the same as those for 
the 2015 Southern Hemisphere influenza season (http://www.who.int/influenza 
/vaccines/virus/candidates_reagents/2015_south/en/), but include two changes from 
the 2014-2015 U.S. influenza vaccine composition: the H3N2 virus, and one of the B 
virus components. 
 With regard to the H1N1 vaccine component, a review of surveillance data showed that 
there has been little antigenic or genetic drift with circulating H1N1 viruses, and so the 
same influenza virus will be used for vaccine production.  
 With regard to the H3N2 component of the vaccine, a review of surveillance data 
showed that there has been substantial genetic change and antigenic drift among 
circulating H3N2 viruses since A/Texas/50/2012 was selected as the 2014-2015 H3N2 
vaccine component. 
o Multiple genetic groups of influenza A (H3N2) viruses are circulating globally. 
o Most (but not all) of circulating H3N2 viruses are antigenically similar to the 
influenza A (H3N2) virus selected for the 2015 Southern Hemisphere vaccine 
(A/Switzerland/9715293/2013).  
o The recommended H3N2 virus for the United States 2015-2016 vaccine is 
A/Switzerland/9715293/2013.   
o A/Switzerland/9715293/2013 is from a genetic group of H3N2 influenza viruses 
called "3C.3a". 
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o Testing suggests A/Switzerland/9715293/2013 should protect against most (but 
not all) currently circulating H3N2 viruses. 
 With regard to the influenza B component of the vaccine, a review of surveillance data 
showed that both lineages of influenza B viruses - B/Yamagata and B/Victoria - 
circulated globally this past year, with B/Yamagata viruses predominating.  
 Among B/Yamagata-lineage viruses, data from global influenza surveillance show that 
an increasing percentage have been antigenically similar to B/Phuket/3073/2013, 
which is the recommended component for the 2015-2016 United States vaccine.  
 More information is available on the FDA VRBPAC web site (http://www.fda.gov 
/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/Va
ccinesandRelatedBiologicalProductsAdvisoryCommittee/ucm427602.htm) and in a 
Question and Answer (http://www.who.int/influenza/vaccines/virus/recommendations 
/201502_qanda_recommendation.pdf) document posted on the WHO web site.   
 
Influenza-Associated Pediatric Deaths 
 Five influenza-associated pediatric deaths were reported to CDC this week.  
 A total of 133 influenza-associated deaths have been reported during the 2014-2015 
season. 
 Because of confidentiality issues, CDC does not discuss or give details on individual 
pediatric death cases. 
 Additional information regarding pediatric deaths is available through the Influenza-
Associated Pediatric Mortality Surveillance System at 
http://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html. 
 A pediatric death is a death in a person who is a U.S. resident and younger than 18 
years old resulting from a clinically compatible illness with influenza that is confirmed 
by an appropriate laboratory test. 
 During the 2013-2014 influenza season, a total of 110 influenza-associated pediatric 
deaths were reported to CDC.  
 A review of the available pediatric death reports from the 2013-2014 season indicates 
that: 
o Of the 106 deaths in which the child’s medical history was known, 54% occurred 
in children who had underlying medical conditions that placed them at high risk 
of developing serious flu-associated complications. However, 46% had no 
recognized underlying health problems.  
o About 80% of pediatric deaths occurred in unvaccinated children.  
o These proportions are largely consistent with what has been seen in the past.  
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 Since 2004, when flu-associated pediatric deaths became a nationally notifiable 
condition, the number of deaths reported to CDC each season has ranged from 37 
(2011-2012 season) to 171 (2012-2013 season).  
 During the 2009 H1N1 pandemic — April 15, 2009 to October 2, 2010 — 358 pediatric 
deaths were reported to CDC.  
 These deaths are a somber reminder of the danger flu poses to children.  
 Typically, most flu-related pediatric deaths occur in children who have not been 
vaccinated against flu.  
 Among children 6 months and older, 80% to 85% of flu-related pediatric deaths occur 
in children who have not been vaccinated. 
 The single best way to protect children against seasonal flu and its potential severe 
consequences is to have them receive a seasonal flu vaccine each year. 
 Among children, vaccination is especially important for those younger than 5 years of 
age and those of any age with an underlying medical condition like asthma; a 
neurologic, neuromuscular or neurodevelopmental disorder (http://www.cdc.gov 
/flu/protect/neurologic-pediatric.htm); or immune suppression. These children are at 
higher risk of serious complications if they get the flu.  
 Yearly vaccination also is especially important for people who come in contact with 
high risk children in order to protect the child (or children) from the flu.  
 Even previously healthy children can become seriously ill if they get the flu. Data on 
laboratory-confirmed influenza hospitalizations collected through FluSurv-Net during 
the 2013-2014 flu season indicated that 50.3% of children hospitalized with the flu had 
no identified underlying medical conditions.  
 Flu-associated deaths in children younger than 18 years old should be reported 
through the Influenza-Associated Pediatric Mortality Surveillance System. The number 
of flu-associated deaths among children reported during the 2014-2015 flu season is 
updated each week and can be found at http://www.cdc.gov/flu/weekly/. 
 Additional information about the pediatric deaths, including basic demographics, 
underlying conditions and week and place of death, for the 2014-2015 season as well 
as past influenza seasons, is available through the Influenza Associated Pediatric 
Mortality application of FluView Interactive at 
http://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html. 
 
 
